Trastuzumab Biosimilars in India

Several — more than for any other cancer biologic sold in India. The reference product is Roche's trastuzumab, marketed internationally as Herceptin and in India as Herclon and Biceltis. Indian similar biologics on the market include CANMAb, Hertraz, Vivitra and Eleftha. Availability varies by city and by hospital pharmacy.

Trastuzumab is a HER2-targeted monoclonal antibody, approved for HER2-positive breast cancer and for HER2-positive gastric and gastro-oesophageal cancer. It is on the World Health Organization's Model List of Essential Medicines and, in India, on the National List of Essential Medicines. Its regulatory status here is settled: the molecule is long approved by CDSCO, and multiple similar biologics have been approved and marketed since 2014.

One clarification that saves families a wasted search: trastuzumab emtansine and trastuzumab deruxtecan are not biosimilars of trastuzumab. They are antibody-drug conjugates — different medicines, with different approved indications, different side effects and their own prices. A trastuzumab biosimilar is not a cheaper version of either.

Enough to change whether a course is affordable at all. Reported Indian prices for a 440 mg vial have moved from roughly ₹75,000 in 2013 to a launch MRP of ₹19,995 for one product in 2019. Trastuzumab also sits under price control, so a notified ceiling caps every brand, the originator included.

Two forces acted at once here, and that is what makes trastuzumab unusual. Competition pulled the cheapest brands down as more suppliers entered. Price control then pulled the most expensive brand down as well, because trastuzumab is a scheduled formulation under the Drug Prices Control Order.

Where the ceiling price comes from. Trastuzumab entered the National List of Essential Medicines in 2015 and remains on the 2022 list. That makes it a scheduled formulation, so the National Pharmaceutical Pricing Authority notifies a maximum price per pack that no brand may exceed, revised each year against the wholesale price index. Very few immunotherapy medicines have this. None of the immune checkpoint inhibitors do.

Three questions that move the total more than the brand does. How many cycles has the oncologist planned — a year of adjuvant treatment is usually about 17 to 18 three-weekly cycles. What dose does body weight give, since the loading dose is higher than the maintenance dose. And does the hospital use 440 mg multi-dose vials efficiently across patients treated the same day, because wasted drug is still billed drug. Asking for an itemised quote, with the drug separated from day-care, monitoring and consultation charges, makes all three visible.

Regulators treat an approved biosimilar as comparable, not identical. To be approved in India, a similar biologic must show comparable quality, safety and efficacy against the reference product. Indian trastuzumab biosimilars have been in routine oncology use since 2014. That is twelve years of real-world use, which is more experience than any newer biosimilar class has.

The pathway is the Guidelines on Similar Biologics, issued by CDSCO with the Department of Biotechnology. They first took effect in September 2012, were revised in 2016 and revised again in 2025. Approval requires analytical characterisation against the reference product, non-clinical data, comparative pharmacokinetics and comparative clinical data where required. Extrapolation to further approved indications is permitted where the mechanism of action and the analytical evidence support it, rather than being studied again in full each time.

Two honest caveats belong here. Early Indian approvals in this class attracted regulatory and legal scrutiny, and part of why the guidelines were tightened in 2016 and again in 2025 is that the first framework was thinner than the one applied today. And India operates no separate interchangeability designation of the kind the United States uses, so the brand a patient receives is a prescribing decision recorded cycle by cycle — not an automatic substitution made at the pharmacy counter. If a brand change is proposed part-way through a course, it is reasonable to ask why, and to have the answer written in the file.

What is not in dispute is the biology. Trastuzumab does something only where the tumour overexpresses HER2. In HER2-positive early breast cancer, adding it to chemotherapy is standard of care in NCCN and ESMO guidance and is intended to lower the chance of the cancer returning; how much benefit an individual gets depends on stage, tumour biology and the rest of the plan. In HER2-negative disease, no brand of trastuzumab — reference product or biosimilar — does anything at all.

Most people with breast cancer are not candidates for trastuzumab, and no price makes them one. The medicine only acts on tumours that overexpress the HER2 protein. Eligibility is decided by a pathology report, long before cost enters the conversation.

• Not for HER2-negative cancer. Roughly 15 to 20 per cent of breast cancers test HER2-positive. If a report reads IHC 0 or 1+, or IHC 2+ with a negative in-situ hybridisation test, trastuzumab is not part of that treatment plan at any price. "HER2-low" is a separate category and is not an indication for trastuzumab itself.
• Not for anyone whose heart pumping function is already significantly reduced, without cardiology input. Trastuzumab can lower the heart's ejection fraction. An echocardiogram or MUGA scan is done before starting and repeated at intervals during treatment. Existing heart failure or a low baseline reading can mean it is deferred, monitored more closely, or not used.
• Not in pregnancy. Trastuzumab can harm a developing baby. Effective contraception is advised during treatment and for a period afterwards; the exact interval is set by the treating team.
• Not a substitute for the rest of the plan. It is given alongside surgery, chemotherapy or radiotherapy, not instead of them. Choosing it in place of a recommended treatment is not a cost saving.
• Not the same medicine as trastuzumab emtansine or trastuzumab deruxtecan. Those are antibody-drug conjugates with their own indications, side effects and prices. A trastuzumab biosimilar is not a lower-cost version of either.

This page is also not a tool for choosing a brand. Which trastuzumab product a patient receives is the treating oncologist's prescribing decision, recorded cycle by cycle, and it depends on what the hospital's licensed pharmacy stocks. Asking whether an approved biosimilar exists for a medicine already prescribed is a different and entirely reasonable question, and one a treating team can answer directly.

Not in the checkpoint-inhibitor sense. Trastuzumab is a monoclonal antibody that binds the HER2 protein on cancer cells. Part of how it works is by marking those cells for destruction by the patient's own immune cells, which is why it is often filed under immunotherapy in India. It does not release a brake on T cells.

Pembrolizumab and nivolumab work the other way round. They block a checkpoint signal so that T cells already capable of recognising the tumour are no longer switched off. Trastuzumab points the immune system at a specific target instead. Both are antibodies; the similarity ends there.

The distinction is not academic when a family is budgeting. Trastuzumab has a competitive biosimilar market and a notified price ceiling. The checkpoint inhibitors, as of August 2026, have neither for most molecules. A cost estimate built on trastuzumab numbers will be badly wrong for a checkpoint inhibitor, and the reverse is also true. Immunotherapy at CION sets out what that class of treatment does and does not do, and Immunotherapy Medicines Explained is the index of individual molecules and their Indian cost picture.

That prices fall in stages, not at launch. India's first trastuzumab biosimilars arrived in 2014 at a modest discount. The steep fall came five years later, once several suppliers were competing and price control had been applied. Families waiting on a cheaper checkpoint inhibitor should read that timeline carefully.

The sequence is worth setting out plainly, because it is the closest thing India has to a completed biosimilar case study. Approval and launch in 2014. More suppliers over the following years. Inclusion on the National List of Essential Medicines, which brought a ceiling price applying to every brand. Then, in 2019, a launch MRP roughly a third of what the market had been charging. Each stage mattered; no single one produced the whole change.

Nivolumab is now at the start of the same road. Its Indian patent lapsed in May 2026 and a domestically manufactured biosimilar launched in January 2026, reported at roughly a quarter of the reference price — a steeper opening discount than trastuzumab managed in 2014. Tishtha: India's Nivolumab Biosimilar and What It Costs covers the reported pricing, and Is a Nivolumab Biosimilar as Good as Opdyta? deals with the comparability question in that molecule specifically.

Two differences make the checkpoint inhibitors a less certain story than trastuzumab was. There is one domestic nivolumab supplier so far, not five, and single-supplier markets do not discount the way crowded ones do. And the checkpoint inhibitors are not on the National List of Essential Medicines, so there is no notified ceiling pressing down from above. Pembrolizumab's Indian patent protection is expected to begin lapsing around 2028-29.

None of which makes waiting a plan. Trastuzumab's price took a decade to settle, and delaying treatment to chase a future price is a clinical decision with clinical consequences, not a financial one.

Two things: what your cover will actually pay, and where the vial came from. A notified ceiling price is not the same as funded treatment, and the widest price spread in Indian oncology is exactly the environment in which a counterfeit vial finds a buyer. Both checks are done before the first cycle, not after.

Coverage: insurance, Aarogyasri, CGHS and ESI

Being on the National List of Essential Medicines does not oblige any scheme to fund a full course. Government scheme packages set their own ceilings for a protocol, and those ceilings do not automatically stretch to cover eighteen cycles of a higher-priced brand. Private policies vary widely in how they treat injectable oncology drugs, and some apply a sub-limit to the drug line specifically.

The practical step is narrow and worth doing early: take the exact molecule, the brand the oncologist has proposed and the planned number of cycles to the insurance or scheme desk before treatment starts, and ask for the applicable limit in writing. Insurance and Biosimilars: Will Your Claim Be Affected? covers what changes, and what does not, when the prescription names a biosimilar rather than the reference brand.

Authenticity and cold chain

Counterfeit and diverted cancer biologics have been reported in the Indian market, and trastuzumab has been among the molecules affected. A large legitimate price spread makes a fake easier to disguise, because an unusually low quote no longer looks impossible. This is patient safety, not caution about a bargain.

Two rules follow, and neither should be softened. These medicines should be dispensed and administered through the treating hospital's own licensed pharmacy — never sourced privately, through an intermediary, or online, however genuine the offer looks. And it is entirely reasonable to ask to see the vial, the batch number, the invoice and the cold-chain record before infusion. Trastuzumab is stored refrigerated; a vial that has spent time warm is not safe to use, whatever the label says. Asking is routine verification, not an accusation.

• Insurance and Biosimilars: Will Your Claim Be Affected? — what a biosimilar prescription changes on a claim, and what it does not.
• Tishtha: India's Nivolumab Biosimilar and What It Costs — the checkpoint inhibitor now at the stage trastuzumab reached in 2014.
• Is a Nivolumab Biosimilar as Good as Opdyta? — the comparability question applied to a much newer molecule.
• Immunotherapy Medicines Explained — the index of checkpoint inhibitors, biosimilars and molecule-by-molecule cost pages.
• Immunotherapy at CION — what this class of treatment does, who it suits, and who it does not.

Editorial information about a medicine and its biosimilars — not an offer, a price list, or a recommendation to use any named product, and no comparative quality claim between manufacturers. All pricing, regulatory and patent statements are indicative and dated to August 2026, drawn from published manufacturer announcements, NPPA ceiling-price notifications, CDSCO regulatory guidance and reported Indian coverage. Whether trastuzumab applies to a particular cancer, and in which brand, is a decision for the treating oncologist on the basis of a HER2 test result.